马上注册登录，享用更多感控资源，助你轻松入门。
您需要 登录 才可以下载或查看，没有账号？注册
|
×
Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobialAmerican Journal of Infection Control Volume 35, Issue 8, Pages 521-526 (October 2007)
Gerald A. Denys, PhD, D(ABMM)a, Kim M. Koch, BS, MT(ASCP)a, Michael J. Dowzicky, MSb
Background
Gram-positive isolates were collected from 76 medical centers within the 9 census regions across the United States.
Methods
Antimicrobial susceptibilities were determined according to Clinical and Laboratory Standards Institute guidelines.
Results
Vancomycin resistance among Enterococcus faecium isolates varied from 45.5% (New England) to 85.3% (East South Central). The lowest concentrations at which 90% of the isolates were inhibited (MIC90) were for tigecycline (0.06-0.12 μg/mL) and for linezolid (2-4 μg/mL). Methicillin-resistant Staphylococcus aureus (MRSA) varied from 27.4% (New England) to 62.4% (East South Central). All MRSA were susceptible to tigecycline, linezolid, and vancomycin. Penicillin-nonsusceptible Streptococcus pneumoniae ranged from 23.3% in the Pacific region to 54.5% in the East South Central region. Tigecycline, imipenem, levofloxacin, linezolid, and vancomycin all maintained MIC90 of ≤1 μg/mL against penicillin-nonsusceptible S pneumoniae in vitro, irrespective of region.
Conclusion
This study demonstrates the variable rate of antimicrobial-resistant gram-positive organisms in the United States. Tigecycline may make a useful addition to the antimicrobial armamentarium. |
发表于 2007-10-22 23:05
发表于 2007-10-28 16:24